Arvinas Inc

Затворен

СекторЗдравеопазване

9.32 -0.43

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.03

Максимум

9.36

Ключови измерители

By Trading Economics

Приходи

227M

169M

Продажби

234M

250M

P/E

Средно за сектора

35.385

57.371

EPS

2.58

Марж на печалбата

67.841

Служители

246

EBITDA

216M

159M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+59.83% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

74M

594M

Предишно отваряне

9.75

Предишно затваряне

9.32

Настроения в новините

By Acuity

47%

53%

145 / 340 Класиране в Healthcare

Arvinas Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.08.2026 г., 19:56 ч. UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21.08.2026 г., 19:56 ч. UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20.08.2026 г., 20:01 ч. UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19.08.2026 г., 19:26 ч. UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17.08.2026 г., 19:16 ч. UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14.08.2026 г., 19:46 ч. UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13.08.2026 г., 19:46 ч. UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11.08.2026 г., 19:26 ч. UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10.08.2026 г., 19:56 ч. UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7.08.2026 г., 19:51 ч. UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6.08.2026 г., 19:46 ч. UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5.08.2026 г., 20:03 ч. UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4.08.2026 г., 20:02 ч. UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3.08.2026 г., 19:46 ч. UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31.07.2026 г., 20:06 ч. UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29.07.2026 г., 16:36 ч. UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28.07.2026 г., 20:06 ч. UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24.07.2026 г., 19:26 ч. UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22.07.2026 г., 20:06 ч. UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21.07.2026 г., 20:06 ч. UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Сравнение с други в отрасъла

Ценова промяна

Arvinas Inc Прогноза

Ценова цел

By TipRanks

59.83% нагоре

12-месечна прогноза

Среден 14.96 USD  59.83%

Висок 21 USD

Нисък 8.68 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Arvinas Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

5

Купи

6

Задържане

0

Продай

Настроение

By Acuity

145 / 340 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat